Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 19/20 | 0.63 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.63 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.63 |
| ▸ | ITGA5 | P08648 | 7/20 | 0.63 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207638 | 0.90 | ITGAV (0.77) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL4203222 | 0.90 | ITGB1 (0.65) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL4242258 | 0.87 | ITGAV (0.82) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL4196184 | 0.87 | ITGAV (0.65) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL4065068 | 0.87 | ITGAV (0.69) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL4205663 | 0.86 | ITGB1 (0.65) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL4246848 | 0.84 | ITGAV (0.74) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL4248480 | 0.84 | ITGAV (0.61) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL4207191 | 0.78 | ITGAV (0.87) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL4194296 | 0.78 | ITGB1 (0.77) | ITGAVITGB3ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | claimed |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008093065-A1 | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008093065-A1 | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGAL | ITGAV 9/4885ITGB3 12/4885ITGB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.